We are live on ! Find out more
INMB icon

INmune Bio
INMB

11 hedge funds and large institutions have $1.62M invested in INmune Bio in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

19,388% more capital inflows, than outflows

Capital inflows: $1.75M | Capital outflows: $9K

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

57% more funds holding

Funds holding: 7 → 11 (+4)

2.17% more ownership

Funds ownership: 0.37% → 2.54% (+2.2%)

Holders
11
Holders Change
+4
Holders Change %
+57.14%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Financial Advocates Investment Management
Financial Advocates Investment Management
Washington
+$1.66M
2
Deutsche Bank
Deutsche Bank
Germany
+$59.2K
3
Covington Capital Management
Covington Capital Management
California
+$7.4K
4
BlackRock
BlackRock
New York
+$6.71K
5
Bank of America
Bank of America
North Carolina
+$6.65K

Top Sellers

Rank Fund Capital Flow
1
TRUE Private Wealth Advisors
TRUE Private Wealth Advisors
Oregon
-$9K

INMB Hedge Fund Activity: Q3 2019 in Review

11 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2019, worth a combined $1.62M — up 332% from $375K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new INMB positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Financial Advocates Investment Management, opening a new position worth an estimated $1.66M. The largest seller was TRUE Private Wealth Advisors, exiting entirely with an estimated $9K sold.

  • 11 institutional investors held INmune Bio (INMB) as of Q3 2019, up from 7 in Q2 2019.
  • Funds reported $1.62M of INmune Bio stock for Q3 2019, up 332% quarter-over-quarter.
  • 5 funds opened new INmune Bio positions in Q3 2019 and 1 closed out, a net change of +4 holders.
  • The largest INmune Bio buyer in Q3 2019 was Financial Advocates Investment Management, an estimated $1.66M added.
  • The largest INmune Bio seller in Q3 2019 was TRUE Private Wealth Advisors, an estimated $9K sold.

Based on aggregated 13F filings for Q3 2019.